Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma
{{output}}
The outcomes of transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are generally poor but much improved by novel targeted therapies and immunotherapies. Tafasitamab plus lenalidomide is an approved regimen for p... ...
